ProtoKinetix announces the initiation of a program testing AAGP to develop a potential therapy to treat dry eye disease (DED). AAGP has demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations, according to a company news release.
Before efficacy testing can commence, an eye irritation study will be conducted in accordance with both industry and regulatory requirements. This testing has been contracted to ITR Laboratories of Montreal. This testing is scheduled to commence in early December with results before January 2020.
In anticipation of a successful result from ITR Laboratories, EyeCRO, from Oklahoma City, have been contracted to conduct the efficacy testing. This testing will involve topical application of AAGP and evaluations of its effects on ocular inflammation. This program will commence in early January 2020 and is expected to run for 3-4 months.